Therap-I MAB Kit

The Go Medical Therap-I MAB Kit is a sterile tubing system which enables the transfer of radioactive proteins between a labeling (reaction) vessel and a purification column using peristaltic pumps.  The MAB kit is supplied without reagents, pumps and the purification column, which will be provided by the client.


Product History

The MAB kit was developed upon request from, and in conjunction with, Professor Harvey Turner and his research group at the Department of Nuclear Medicine, Fremantle Hospital. The requirement specified by Professor Turner was for the design and construction of a sterile tubing system which enabled the transfer of radioactive proteins between a labeling vessel and a purification column using peristaltic pumps.

Since 2001, multi-centre clinical trials of the radiopharmaceutical infusion pump system have been undertaken under the supervision of Dr. Harvey Turner in various locations throughout Australia.

The Therap-I MAB kit is regarded as laboratory equipment rather than a Medical Device.


Device Variants

Catalogue NumberDescription
THERAPI-01 Therap-I MAB Kit


Clinical Papers

The following papers have evaluated the techniques used in radio immunotherapy that the Therap-I MAB kit has been developed specifically for.

  1. Bishton, M.J. et al., 2008. A prospective study of the separate predictive capabilities of 18[F]-FDG-PET and molecular response in patients with relapsed indolent non-Hodgkin’s lymphoma following treatment with iodine-131-rituximab radio-immunotherapy. Haematologica, 93(5), pp.789–90. Available at:
  2. Bishton, M.J. et al., 2008. Repeat treatment with iodine-131-rituximab is safe and effective in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma who had previously responded to iodine-131-rituximab. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 19(9), pp.1629–33. Available at:
  3. Claringbold, P.G. et al., 2011. Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 38(2), pp.302–11. Available at:
  4. Leahy, M.F. et al., 2006. Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin’s lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24(27), pp.4418–25. Available at:
  5. Leahy, M.F. & Turner, J.H., 2011. Radioimmunotherapy of relapsed indolent non-Hodgkin lymphoma with 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood, 117(1), pp.45–52. Available at:
  6. Turner, J.H. et al., 2003. 131I-Anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer biotherapy & radiopharmaceuticals, 18(4), pp.513–24. Available at:
  7. Turner, J.H., 2009. Defining pharmacokinetics for individual patient dosimetry in routine radiopeptide and radioimmunotherapy of cancer: Australian experience. Current pharmaceutical design, 15(9), pp.966–82. Available at:
  8. Turner, J.H., 2012. Outpatient therapeutic nuclear oncology. Annals of nuclear medicine, 26(4), pp.289–97. Available at: